New Key Statistics Module, Z-Score and F-Score
NAS:TSHA Key Ratios
| Market Cap $ M | 395.54 |
| Enterprise Value $ M | 290.14 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 4.49 |
| Price/Sales | 45.84 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 9.00 |
| EPS (TTM) $ | -0.04 |
| Beneish M-Score | -2.62 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -13.20 |
| EV-to-EBITDA | -14.04 |
| PEG | -- |
| Shares Outstanding M | 204.94 |
| Net Margin (%) | -229.67 |
| Operating Margin % | -831.93 |
| Pre-tax Margin (%) | -229.67 |
| Quick Ratio | 5.51 |
| Current Ratio | 5.51 |
| ROA % (ttm) | -12.62 |
| ROE % (ttm) | -41.05 |
| ROIC % (ttm) | -115.25 |
| Dividend Yield % | -- |
| Altman Z-Score | -1.47 |
TSHA Number of Guru Trades
TSHA Volume of Guru Trades
Gurus Latest Trades with NAS:TSHA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:TSHA is held by these investors
Total 1
Taysha Gene Therapies Inc Insider Transactions
No Available Data
News about NAS:TSHA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers